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Abstract. The role of the neurohypophyseal peptide oxytocin
(OT) and its receptor (OTR) in the breast has been described
mainly in relation to breast feeding or to neoplastic growth
regulation. We demonstrate here the presence of OT synthesis
within the breast under both physiological and neoplastic
conditions. In order to clarify whether normal epithelial and
myoepithelial cells could synthesize OT, the two different cell
types were separated using immunomagnetic technique after
enzymatic digestion of breast specimens obtained during
reductive mastoplasty. The freshly isolated cells as well as
primary stabilized cultures derived from purified normal breast
epithelial and myopithelial cells were then studied. Both
epithelial and myoepithelial cells contained the mRNA for
OT and OTR; however, only myoepithelial cells showed an
effective OT synthesis and detectable peptide release in the
culture medium. Moreover, OT expression was studied at
mRNA and protein level in 10 human breast carcinoma cell
lines. OT mRNA was present in half (5 out of 10) of the
breast carcinoma cell lines tested, and OT was synthesized
and released in the cell medium, irrespective of the estrogen
receptor status of the different cell lines. However, in the
two ER+ cell lines actively producing OT, such synthesis was
significantly increased following estradiol (E2) treatment.
These data altogether suggest the existence of a local OT
source within the normal as well as within the neoplastic breast,
and that such synthesis can be modulated by E2.
Introduction
The hypothalamic nonapeptide oxytocin (OT) is known to
play a role in many biological functions including lactation,
parturition, sexual and maternal behavior (1), control of food
intake (2), and regulation of cells growth under both physio-
logical and neoplastic conditions (3,4). These actions are all
mediated through the activation of specific G-coupled trans-
membrane receptors (OTR) (5).
In the breast, OTR were detected in contractile myo-
epithelial cells, in primary breast carcinomas and in breast
carcinoma cell lines (6-8). In breast carcinoma cells, OT
regulates cell proliferation via OTR, determining inhibition
of cell growth in vitro and in vivo (8-11). In a previous study
on breast carcinoma cell lines we demonstrated also that OT
modulates the expression of estrogen receptor · (ER·) in
MCF7 cells, both at mRNA and protein level (12). Moreover,
estradiol (E2) regulates OTR binding and expression in MCF7
ER-positive breast cancer cell line (13). All these findings taken
together demonstrate the existence of a functional ER/OTR
interplay in breast cancer which can be possibly involved in
different biological effects of both ligands, E2 and OT. How-
ever, although the presence of OTR in breast cancer cells and
primary carcinomas has been extensively investigated, no data
are available to date on the eventuality of a local synthesis of
OT in normal breast epithelial and myoepithelial cells and/or
in neoplastic breast cells.
Actually, the OT synthesis by neoplastic cells in general
has been scarcely investigated. Pequeux et al described OT
synthesis, as well as OTR expression, in cell lines from human
small cell carcinoma of the lung (14). In this model, the authors
demonstrated the existence of a functional OT-mediated auto-
crine-paracrine signaling actively implicated in growth and
development of this type of tumor (14). On the contrary, in
another OTR-positive carcinoma displaying a potential endo-
crine differentiation, such as prostatic carcinoma, the mRNA
for OT was absent in neoplastic cells (15).
The aim of the present work was to investigate oxytocin
production by normal breast-derived cells, either of myo-
epithelial or epithelial origin, as well as in breast carcinoma
cell lines. According to the previous reported data on the
estrogen-OT interplay, we also aimed to verify the possible
effect of E2 on the OT secretion and on OTR regulation in
these different cell subtypes. The presence of OT-mRNA was
verified by reverse transcriptase polymerase chain reaction
(RT-PCR). The effective synthesis and release of OT, in
absence or presence of E2, was assessed by an enzyme immuno-
assay in cell supernatants. Finally, the effect of E2 on OTR
modulation was investigated by flow cytometry analysis.
Materials and methods
Cell lines and cell culture. Human breast cancer cell lines
(MCF7, T47D, Hs578T, SKBR3, MDA-MB4353, BT474,
BT549, BT20, ZR75 and MDA-MB-231) were all purchased
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from the ATCC (Rockville, MD). All cells were grown in a
5% CO2 humidified atmosphere in RPMI, DMEM or ISCOVE
medium (Gibco, Paisley, Scotland) with 10% FCS (Gibco),
penicillin/streptomycin and fungizone (Gibco).
Tissue collection and cell purification. Human mammary
tissues were obtained as discard material from six reduction
mammoplasties, following informed consent of the patient.
The glandular cells were separated from the stromal cells with
a procedure involving dissection, enzymatic digestion and
immunomagnetic cell separation. Tissues were processed in a
digestion mixture with collagenase type IA 200 U/ml (Sigma-
Aldrich, St. Louis, MO) and hyaluronidase 100 U/ml (Sigma-
Aldrich) as previously described (16,17). The enzymatic
reaction was stopped when stroma was broken down and
basement membrane was digested. Mammary epithelial and
myoepithelial cell purification was performed by Dynabeads
Magnetic Separation (Dynal Biothec, Oslo, Norway). Myo-
epithelial cells were selected using ·CD10 primary antibody
(Novocastra, 1:50, clone 56 c6, Bentonlane, Newcastle, UK)
incubated for 1 h at 4˚C and using Dynabeads M-450 goat
anti-mouse IgG (1-2x107 beads/ml sample) for 45 min at 4˚C,
providing gentle mixing. The resulting complex was removed
from the suspension by means of a magnet. Epithelial cells
were then selected using EMA monoclonal antibody 1:50
(clone E29, Dako, Glostrup, Denmark) following the
previously detailed procedure. Using ICC procedures with the
specific antibodies, the phenotype of the separated cells was
verified and reconfirmed in cells seeded on a glass coverslip.
Purified mammary cells were then grown in culture flask in
DMEM/Ham's F12 1:1 medium (Sigma) supplemented with
10% FCS, 0.01 mg/ml insulin, 500 ng/ml hydrocortisone,
20 ng/ml EGF, 100 ng/ml cholera toxin. In addition, to verify
the results obtained in the freshly separated cells, we used
two established cultures of human myoepithelial and epithelial
cells respectively, a kind gift of Professor S.R. Lakhani's
group (Department of Histopathology, Royal Free and
University College Medical School, University College,
London, UK) (18).
Detection of OTR and OT mRNA by RT-PCR in breast cancer
cell lines, and purified cell components from normal breast
tissue. Total RNA was extracted from the cell lines and the
different cell types obtained by breast tissue digestion and
dynabeads separation using the TriRiagent extraction kit
(Molecular Research Center Inc., Cincinnati, OH, USA)
following manufacturer's recommendations. The concentration
of RNA was estimated by spectrophotometry, and RNA
degradation was assessed by 1% agarose gel electrophoresis.
Total RNA (1 μg) was digested to avoid DNA contamination
with 10 U of RNase-free DNase (Boehringer-Mannheim,
Mannheim, Germany) in a 10 μl solution containing 2 mM
MgCl2 at RT for 10 min, then heated for 5 min at 70˚C to
inactivate DNase. Oligodeoxythymidine primer (40 pM) (oligo
dT16) was then added and the solution was heated at 70˚C for
10 min, then chilled on ice to allow primer hybridization. The
final solution was reverse-transcribed with 100 U of Super-
script Reverse Transcriptase (Gibco-BRL, Gaithersburg, USA),
and complementary DNA (cDNA) was generated in a 50 μl
final reaction volume containing 50 mM Tris-HCl pH 8.3,
75 mM KCl, 3 mM MgCl2, 10 mM DTT, 1 mM dNTPs and
20 U of RNasin (Promega, Madison, WI, USA). The solution
was heated at 37˚C for 90 min, then the enzymes inactivated
by heating at 70˚C for 10 min. Negative control samples for
further PCR amplification included omission of the reverse
transcriptase enzyme.
RNA quality was assessed by amplification of ß2-micro-
globulin mRNA. OTR primers were designed according to
Takemura et al (19). Primer sequences and location for OTR,
OT and ß2-microglobulin PCR primers are listed in Table I.
PCR experiments were carried out in a final volume of 10 μl
containing 1 μl of cDNA, 1 μM of sense and antisense primer,
200 μM dNTP, 1X PCR buffer (10 mM Tris-HCl pH 8.3,
50 mM KCl) (AmpliTaq, Perkin-Elmer, Roche, NJ), 1.5 mM
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Table I. Sequences of OT and OTR PCR primers and Southern probes.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Primer Sequence Position GenBank accession
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
ß2-microglobulin
Forward 5'-ACC CCC ACT GAA AAA GAT GA-3' 284-303 XM_007650
Reverse 5'-ATC TTC AAA CCT CCA TGA TG-3' 378-397 XM_007650
OTR
Forward 5'-CCT TCA TCG TGT GCT GGA CG-3' 1469-1488 NM_000916
Reverse 5'-CTA GGA GCA GAG CAC TTA TG-3' 1840-1859 NM_000916
Probe 5'-GGA GCA GCA CAG GAA GCG GTC CAC 1618-1665 NM_000916
GAG TTC GTG GAA GAG GTG GCC CGT-3'
OT
Forward 5'-ACC ATT TCT GGG GTG GCT AT-3' 41-50 AW270827
Reverse 5'-GGT CTT GGG CCT CTG CTG-3' 172-189 AW270827
Probe 5'-GTG TTC GGA GCC ATC AAG TT-3' 89-108 AW270827
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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MgCl2 and 0.5 U of Taq polymerase (AmpliTaq Gold, Perkin-
Elmer). Each reaction consisted of 35 cycles of denaturation
at 94˚C for 45 sec, annealing at 55˚C (ß2-microglobulin and
OTR) and 61˚C (OT) for 1 min, and extension at 72˚C for
1 min. PCR products were then visualized under UV light in
1% agarose gels containing ethidium bromide. MCF7 human
breast carcinoma cells and normal human hypothalamus
(obtained from autopsy) were used as positive controls for
OTR and OT, respectively. Negative control samples included
omission of cDNA in the PCR mixture.
To further test RT-PCR product specificity, Southern blot
analysis (SBA) was performed. Probe sequences are reported
in Table I. Membranes were hybridized at 42˚C overnight
with 25 pmols of digoxigenin-labelled OTR oligonucleotide
probe. The membranes were then washed with 2X SSC-
0.1% SDS for 10 min at 42˚C and 0.5X SSC-0.1% SDS for
30 min at 42˚C. Digoxigenin-labeled specific hybridization
was visualized using an immunological detection system
(Boehringer-Mannheim) employing anti-digoxigenin anti-
bodies conjugated with alkaline phosphatase. Detection was
performed using the chemiluminescent substrate disodium 3-
(4-methxyspiro; 1,2-dioxetane-3,2-(5-chloro)tricyclo(3.3.1.3,7)
decan;-4-yl) phenylphosphate CSPD (Boehringer), according
to the manufacturer's instructions. All blots were exposed to
X-ray film with intensifying screens at RT for 3 h.
Dosage of OT in the cell supernatants. The production of OT
by epithelial and myoepithelial cells derived from normal
breast, as well as by breast carcinoma cell lines was assessed
by means of an enzyme immunoassay (Oxytocin Enzyme
Immunoassay kit, Assay Designs, Ann Arbor, MI). The
presence of OT in the cell supernatants and in standard
culture medium was tested following the kit instructions and
peptide concentrations were determined by comparison to the
provided standard. OT concentrations were determined both
under basal culture conditions as well as following 12 or 48 h
of treatment with 10 nM E2.
Modulation of OTR expression following E2 treatment in
breast carcinoma cell lines. Surface expression and modulation
of OTR was investigated by flow cytometry analysis (FACSort,
Becton-Dickinson, Milan, Italy), after treatment with E2 10 nM
for 30 min in two ER-positive breast carcinoma cell lines
(MCF7 and T47D). For OTR detection, 1x106 cells were
incubated with 1 μg of the anti-OTR IF3 mAb (6) for 1 h at
4˚C, and then with the secondary antibody goat anti-mouse
IgM-FITC conjugated (1:40 in PBS) (Sigma-Aldrich) for
45 min at 4˚C. The intensity of fluorescence was recorded on
a logarithmic scale, by scoring at least 20,000 cells/sample;
background fluorescence intensity was obtained by incubating
the cells with the goat anti-mouse immunoglobulin reagent
alone.
Results
OTR and OT mRNA in cell lines, and cell components from
neoplastic and normal breast tissue. The presence of OTR
and OT mRNA was studied in ten breast carcinoma cell
lines, either ER-negative or positive by means of RT-PCR.
The results are summarized in Table II. All the cell lines
expressed OTR mRNA, whereas only 5/10 expressed OT
mRNA. The hormone dependency (ER+ cells) of the tumor
cell line was irrelevant with respect to OT mRNA
expression.
Similarly, the presence of OTR and OT mRNA was tested
in different cell subtypes isolated from specimens of normal
tissues obtained from mastoplasties (both myoepithelial and
epithelial component). RT-PCR was performed either in
purified cell types, following separation, or in established
primary cultures of both myoepithelial and epithelial cells.
The results are summarized in Table III.
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Table II. OT and OTR mRNA detection in human breast
cancer cell lines.
–––––––––––––––––––––––––––––––––––––––––––––––––













Table III. OT and OTR mRNA detection in selected component from human normal breast tissue.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Case Cell type Separation OT mRNA OTR mRNA
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Freshly separated cells Myoepithelial cells Digestion+DB (CD10) + +
Freshly separated cells Epithelial cells Digestion+DB (EMA) + +
Established primary culture Myoepithelial cells + +
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Fig. 1 shows the presence of OTR and OT mRNA
following Southern blot analysis in the cell lines tested.
OT levels detected in the cell culture media. By means of an
immune-enzymatic assay OT concentration were dosed in the
cultured medium of three breast carcinoma cell lines which
were previously shown to contain OT mRNA by RT-PCR
(T47D, BT474, BT20). OT release in the culture medium
was evaluated in the epithelial and myoepithelial cells purified
from normal breast tissue. Table IV summarized the results
obtained, comparing the OT levels in the cell medium before
culture, in the medium following 12 and 48 h of culture, in
the medium following 12 and 48 h of cell culture in presence
of E2 10 nM. In the breast cancer cells studied, the levels of
OT in media collected after 48 h of culture ranged from 10 to
15 pg/ml, compared to 2 to 3 pg/ml concentration in the
mediums alone (p<0.05, by ANOVA). In the two ER-
positive cell lines, E2 determined a significant increase in OT
concentrations (up to a 4.4-fold increase in BT474 and a 8.6
increase in T47D cells at 48 h) (<0.001, treated versus control,
by ANOVA), and had no effect, as expected, in the ER-
negative BT20 cell line. In myoepithelial cells, which displayed
a significant basal OT-secretion (24 pg/ml at 48 h of culture)
non-significant change in OT concentration occurred following
E2 treatment. Finally, normal epithelial cells did not secrete OT.
Data reported in Table IV are mean ± SD of three different
experiments with cells seeded in quadruplicate.
OTR expression following E2 treatment in breast carcinoma cell
lines. The surface expression of OTR following E2 treatment
was investigated by flow cytometry in MCF7 and T47D cells.
In both cell lines, 30 min of 10 nM E2 treatment determined
a 100-fold increase in the OTR expression. Fig. 2 shows
the pattern of OTR expression in T47D following 30 min
incubation with E2 10 nM.
Discussion
In the present study we provide the first demonstration of a
local OT synthesis within the human mammary gland, under
both normal and neoplastic conditions. Specifically, normal
myoepithelial cells synthesize and secrete OT; different
carcinoma cell lines are able to synthesize and release OT;
and E2 is a modulating factor in ER-positive cells involved in
the regulation of such secretion.
The ‘traditional’ known sites of OT production mainly
involve, among others (20), specific hypothalamic regions
(21), ovary (22), heart (23), vasculature (24) and lympho-
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Figure 1. OT and OTR mRNA expression in breast carcinoma cell lines. Southern blot analysis of RT-PCR products of oxytocin receptor (OTR) and its
ligand oxytocin (OT) in 10 human breast carcinoma cell lines (lane 1, MCF7; lane 2, T47D; lane 3, BT474; lane 4, ZR75; lane 5, Hs578t; lane 6, SKBR3;
lane 7, MDA-MB4353; lane 8, BT549; lane 9, BT20; lane 10, MDA-MB-231; C-, negative control including omission of cDNA in the PCR mixture; C+,
positive control corresponding to normal human hypothalamus for OT and BeWo choriocarcinoma cells for OTR). The corresponding base pair sizes were
420 bp and 149 bp, respectively (arrow heads).
Table IV. OT levels (pg/ml) in the cells line supernatants.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
OT at 12 h OT at 48 h
–––––––––––––––––– –––––––––––––––––––
Cell line Medium Basal E2 Basal E2
(pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
BT474 3±1 10±2 38±5 12±2 53±3
T47D 3±2 12±1 96±4 15±3 129±5
BT20 2±1 7±1 6±1 10±1 10±1
Myoepithelial cells 3±1 18±3 20±5 24±5 28±4
Normal epithelial cells 3±1 3±2 4±2 4±1 4±1
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Data are mean ± SD of three different experiments with cells seeded in quadruplicate. Basal levels versus medium in BT474, T47D and
BT20 cells at 12 and 48 h: p<0.05. Basal levels versus E2-treated in BT474, and T47D cells at 12 and 48 h: p<0.001. Statistical analysis
carried out by ANOVA.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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cytes (25). Besides these normal tissues, recently OT synthesis
has been reported in lung small cell carcinoma cell lines as
well (14).
In the mammary gland, the role of OT is mainly related
to lactation (26,27) under physiological conditions and to
regulation of cancer cell growth under neoplastic conditions
(8-10). In both situations myoepithelial or neoplastic
epithelial cells respectively have been reported to express on
their membrane surface functional OTR (6) which can bind
OT derived from circulating blood. The effect of the OT/OTR
binding results in a calcium-mediated contraction, for myo-
epithelial cells (28), and regulation of cancer cell proliferation,
for breast carcinoma cells (8).
In the present study we provide the first evidence of a
local synthesis of OT within the mammary gland. Although
both normal epithelial and myoepithelial cells isolated from
human breast contain the mRNA for OT, only myoepithelial
cells actively produce and release OT in the culture medium.
Such result suggests the possible existence of an unexpected
local autocrine loop involving myoepithelial cells, which are
known to be OTR positive, as reconfirmed in this study in the
purified cell cultures. The role of OT in myoepithelial cells
could be related to differentiation processes: in a previous study
from our group, OT induced myoepithelial cell proliferation
and differentiation in organotypic cultures of mouse mammary
gland obtained from primed animals (29). Therefore, the
existence of an intra-mammary synthesis of OT could represent
a local peptide source directly available for myoepithelial cell
differentiating processes.
In the normal mammary epithelial cells, both freshly
isolated cells and established cultures, despite the presence of
OT mRNA, no active OT synthesis and release in the culture
medium was observed. When we moved from normal
mammary epithelial cells to ten established breast carcinoma
cell lines, we could observe that OT mRNA was present in
50% of the cell lines tested, irrespective to their hormonal
dependency (ER-positive cells) or independency (ER-
negative cells). The presence of the OT gene and the peptide
synthesis in these breast carcinoma cell lines could be
consistent with the subset of breast cancers reported to show
a ‘basal’ phenotype, and to express markers of myoepithelial
differentiation (18).
The OT mRNA present in these 5 out of 10 breast
carcinoma cell lines is used to actively synthesize and
release OT in the culture medium. The OT concentrations
ranged from 7 to 15 pg/ml under basal culture conditions.
Interestingly, such production is significantly increased after
E2 treatment in ER-positive cells (up to an 8-fold increase in
TD47D cells, increasing the peptide concentration to 129
pg/ml). The effect of E2 on these cancer cells is on both the
peptide synthesis and the receptor expression. By flow
cytometry we could demonstrate that E2 treatment
significantly increased the quantity of OT binding sites on
the cell surface of ER-dependent MCF7 and T47D breast
carcinoma cell lines. This observation is consistent with the
one previously reported by Amico and co-workers (13). The
data obtained in the present study seem to support the idea of
a relevant interplay between E2 and the OT/OTR system
within the mammary gland, which can be enhanced by the
evidence of a local intra-tumoral OT source. The E2-OT
interplay probably follows a two-ways roundabout: not only
E2 interferes with OTR expression and OT synthesis as here
reported, but also OT may modulate ER· expression in
breast cancer cells as demonstrated in a previous study from
our group (12). However, ER-negative breast carcinoma cells
also may synthesize OT, indicating that the role of the
peptide is not exclusively limited to a selected ‘steroid-
imprinted’ cell population.
In different cell types, OT is known to play a double
effect on cell proliferation, either inhibitory or stimulating;
i.e., OT inhibits growth of breast carcinoma cells but
enhances proliferation of endothelial cells (3,10,25).
Therefore, this local unexpected OT source within the breast
carcinomas opens complex perspectives into additional
mechanisms regulating tumor growth and possibly
angiogenesis. The levels of OT here dosed in the culture
medium (both under basal condition and following E2
stimulation) are at least 100-fold lower than required (100 nM)
to determine an effect on breast carcinoma cell proliferation.
In contrast, recently we demonstrated (unpublished data) that
low OT concentration (1 nM) could determine migration and
proliferation of tumor-associated endothelial cells derived
from breast carcinomas. Altogether, these data suggest that by
inducing OT synthesis in breast carcinoma cells, E2 could
modulate vascular changes within the neoplastic tissue
through a local paracrine loop. Further studies would be
necessary to verify this challenging preliminary hypothesis.
In conclusion, in this study we provide the first evidence
of a local synthesis of OT within the normal and neoplastic
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Figure 2. OTR modulation by E2 in T47D cells. By flow cytometry OTR
expression in T47D breast cancer cells was significantly increased following
E2 treatment. Dark profiles, unrelated Ab. Each experiment was repeated at
least twice with reproducible results. The levels shown refer to one single
representative experiment.
FL1-Height
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breast, which suggests that this peptide could play an autocrine/
paracrine role in this context, exerting different, various and
possibly still unidentified biological effects.
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